Correction of coagulation in dilutional coagulopathy: use of kinetic and capacitive coagulation assays to improve hemostasis.
The management of dilutional coagulopathy due to fluid infusion and massive blood loss is a topic that deserves a biochemical approach. In this review article, we provide an overview of current guidelines and recommendations on diagnosis and on management of transfusion in acquired coagulopathy. We discuss the biochemical differences between kinetic clotting assays (clotting times) and new capacitive coagulation measurements that provide time-dependent information on thrombin generation and fibrin clot formation. The available evidence suggests that a combination of assay types is required for evaluating new transfusion protocols aimed to optimize hemostasis and stop bleeding. Although there is current consensus on the application of fresh frozen plasma to revert coagulopathy, factor concentrates may appear to be useful in the future.
Schols
Saskia E M
SE
Department of Biochemistry, CARIM, Maastricht University Medical Centre, Maastricht, The Netherlands.
Heemskerk
Johan W M
JW
van Pampus
Elisabeth C M
EC
D001778:Blood Coagulation Disorders / Q000175:diagnosis / Q000628:therapy*; D001780:Blood Coagulation Tests; D001803:Blood Transfusion; D019468:Disease Management; D006487:Hemostasis; D006801:Humans